Overall serious adverse events · people who smoke
Combination showed no clear difference in overall serious adverse events compared with single‐form nicotine replacement therapy (low certainty).
1 finding from 1 review
Treatment withdrawal · people who smoke
It is very uncertain whether combination changes treatment withdrawals compared with single‐form nicotine replacement therapy (very low certainty).
1 finding from 1 review
Smoking cessation ‐ 16 weeks versus 8 weeks · people who smoke
It is very uncertain whether longer changes smoking cessation ‐ 16 weeks versus 8 weeks compared with shorter duration of combination nicotine replacement therapy (very low certainty).
1 finding from 1 review
Smoking cessation · people who smoke
Longer showed no clear difference in smoking cessation ‐ 6 weeks versus 2 weeks compared with shorter duration of combination nicotine replacement therapy (low certainty).
1 finding from 1 review
SAEs · people who smoke
It is very uncertain whether longer changes overall SAEs ‐ 26 weeks versus 8 weeks compared with shorter duration of combination nicotine replacement therapy (very low certainty).
3 findings from 1 review
RR 1.63 [0.6, 4.42]
1 study · 544 participants
Very low
no estimate extracted
1 study · 637 participants
Very low
no estimate extracted
1 study · 987 participants
Very low
Treatment withdrawal · people who smoke
1 finding from 1 review
Overall survival · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower overall survival compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
12‐month survival rates · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower 12‐month survival rates compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower progression‐free survival compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
Tumor response rate · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to higher tumor response rate compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
Toxicity – anemia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet showed no clear difference in toxicity – anemia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Toxicity – neutropenia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet may leads to higher toxicity – neutropenia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Toxicity – thrombocytopenia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet may leads to higher toxicity – thrombocytopenia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Fatigue · adults with breast or prostate cancer receiving radiation therapy alone
1 finding from 1 review
QoL · adults with breast or prostate cancer receiving radiation therapy alone
1 finding from 1 review
Physical performance · adults with breast or prostate cancer receiving radiation therapy alone
1 finding from 1 review
Psychosocial effects Measured at 5‐8 weeks (short term); end scores. Positive SMD values signify better psychosocial effects. · adults with breast or prostate cancer receiving radiation therapy alone
1 finding from 1 review
Overall survival · adults with breast or prostate cancer receiving radiation therapy alone
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Return to work · adults with breast or prostate cancer receiving radiation therapy alone
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with breast or prostate cancer receiving radiation therapy alone
1 finding from 1 review